The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Jul 2015 11:41

RNS Number : 5091S
Advanced Oncotherapy PLC
08 July 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Advanced Oncotherapy Plc

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

ü

Other (please specify):

 

   

 

3. Full name of person(s) subject to the notification obligation: iii

Mr Alberto Colussi

4. Full name of shareholder(s)

(if different from 3.): iv

Mr Alberto Colussi

Brahma AG

5. Date of the transaction and date on which the threshold is crossed or reached: v

7 July 2015

6. Date on which issuer notified:

8 July 2015

7. Threshold(s) that is/are crossed or

reached: vi, vii

Below 18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

GB00B16JQ761

 

242,689,600

242,689,600

27,879,630

27,879,630

214,809,970

2.026%

15.606%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/ConversionPeriod xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 N/A

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exerciseprice

Expirationdate xvii

Exercise/Conversionperiod xviii

Number of votingrights instrumentrefers to

% of voting rights xix, xx

 

N/A

 

 

 

 

 

 

Nominal

Delta

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 242,689,600

 17.63%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Mr Alberto Colussi's direct holding in Brahma AG is 100%

 

Proxy Voting:

10. Name of the proxy holder:

 N/A

11. Number of voting rights proxy holder will cease to hold:

 N/A

12. Date on which proxy holder will cease to hold voting rights:

 N/A

 

13. Additional information:

 N/A

14. Contact name:

 Graham Pughe, AVO Plc

15. Contact telephone number:

 0203 761 4995

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUWORRVWABRAR
Date   Source Headline
3rd Mar 20225:05 pmRNSDirector/PDMR Notification
2nd Mar 20224:10 pmRNSDirector/PDMR Notification
1st Mar 20227:00 amRNSOperational update
28th Feb 20225:00 pmRNSTotal Voting Rights
17th Feb 20224:25 pmRNSExercise of Warrants and Issue of Equity
31st Jan 20225:00 pmRNSTotal Voting Rights
13th Jan 20223:17 pmRNSExercise of Warrants and Issue of Equity
31st Dec 20211:00 pmRNSTotal Voting Rights
13th Dec 20217:00 amRNSTechnical update on delivery of first LIGHT system
10th Dec 20217:00 amRNSHolding(s) in Company
3rd Dec 20215:09 pmRNSHolding(s) in Company
2nd Dec 20211:29 pmRNSIssue of warrants and equity and Loan Extension
30th Nov 20215:00 pmRNSTotal Voting Rights
15th Nov 20218:30 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): On the home straight
10th Nov 202111:23 amRNSHolding(s) in Company
8th Nov 20212:28 pmRNSExercise of Warrants and Issue of Equity
4th Nov 20211:44 pmRNSHolding(s) in Company
27th Oct 20217:00 amRNSPresentation highlights LIGHT system superiority
30th Sep 20215:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSInterim Results
23rd Sep 202111:27 amRNSExercise of Warrants and Issue of Equity
20th Sep 20217:00 amRNSUpdate re admission of Subscription Shares
3rd Sep 20217:00 amRNSUpdate on admission of Subscription Shares
31st Aug 20216:14 pmRNSResult of GM, TVR and clarification re warrants
16th Aug 20214:48 pmRNSExercise of Warrants and Issue of Equity
12th Aug 20211:50 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO) Funded to completion
11th Aug 20217:00 amRNSProposed subscription and issuance of shares
2nd Aug 20213:37 pmRNSResult of AGM
30th Jul 20214:58 pmRNSResult of AGM
13th Jul 20212:19 pmRNSHoldings in company
30th Jun 20217:00 amRNSFinal Results for the year ended 31 December 2020
3rd Jun 20217:00 amRNSSaba Partners sign LOI for LIGHT system
28th May 20215:00 pmRNSTotal Voting Rights
26th May 202110:37 amRNSExercise of Warrants and Issue of Equity
28th Apr 20215:38 pmRNSExercise of Warrants and Issue of Equity
31st Mar 20215:00 pmRNSTotal Voting Rights
12th Mar 20217:00 amRNSStudy shows the potential superiority of LIGHT
11th Mar 20217:00 amRNSExercise of Warrants and Issue of Equity
26th Feb 20215:00 pmRNSTotal Voting Rights
17th Feb 202110:39 amRNSExercise of Warrants and Issue of Equity
22nd Jan 20217:00 amRNSEquity fundraise of c.£5.9m
13th Jan 20217:00 amRNSExercise of Warrants and Issue of Equity
11th Jan 20217:00 amRNSTechnical update
6th Jan 202111:05 amRNSSecond Price Monitoring Extn
6th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:00 amRNSFinancing partnership agreement with DiaMedCare AG
15th Dec 20207:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Leveraging the modularity of LIGHT
23rd Nov 20202:42 pmRNSHolding(s) in Company
17th Nov 20202:02 pmRNSHolding(s) in Company
10th Nov 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.